KW-6356
Sponsors
Kyowa Kirin Co., Ltd., Kyowa Kirin, Inc.
Conditions
Healthy Male SubjectsHepatic ImpairmentParkinson's Disease
Phase 1
A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
CompletedNCT03970798
Start: 2019-05-22End: 2019-07-31Updated: 2019-11-29
A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin
CompletedNCT04070495
Start: 2019-08-27End: 2019-11-19Updated: 2019-11-29
Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356
CompletedNCT04147910
Start: 2019-08-21End: 2019-10-02Updated: 2024-04-25
Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite
CompletedNCT04190654
Start: 2019-11-26End: 2020-03-20Updated: 2024-04-25
A Through QT/QTc Study of KW-6356
CompletedNCT04342273
Start: 2020-03-31End: 2020-09-05Updated: 2020-09-18
Phase 2
A Study of KW-6356 in Subjects With Early Parkinson's Disease
CompletedNCT02939391
Start: 2016-09-30End: 2017-12-08Updated: 2018-03-20
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
CompletedNCT03703570
Start: 2018-09-29End: 2020-04-15Updated: 2020-09-07